

200–1994/0–US–01); U.S. Patent 5,763,613 issued on 09 Jun 1998 (DHHS Reference No. E–200–1994/0–US–02); U.S. Patent 6,140,339 issued on 31 Oct 2000 (DHHS Reference No. E–200–1994/2–US–01); U.S. Patent 6,331,630 issued on 18 Dec 2001 (DHHS Reference No. E–200–1994/2–US–08); U.S. Patent 5,571,919 issued on 05 Nov 1996 (DHHS Reference No. E–201–1994/0–US–01); U.S. Patent 5,789,594 issued on 04 Aug 1998 (DHHS Reference No. E–201–1994/0–US–02); U.S. Patent 5,578,729 issued on 26 Nov 1996 (DHHS Reference No. E–201–1994/1–US–01); U.S. Patent 5,786,482 issued on 28 Jul 1998 (DHHS Reference No. E–201–1994/1–US–03).

According to data recently reported by the World Health Organization (WHO), the death rate from malaria exceeds one million individuals per year. The Public Health Service seeks exclusive or non-exclusive licensee(s) to develop and commercialize the technology claimed within the portfolio of U.S. patents issued and pending, and corresponding international patents issued and pending. These patents and pending applications claim an exceptionally broad universe of novel naphthylisoquinoline alkaloid compounds, and methods of total synthesis thereof. Representative examples of these compounds have been shown to have potent in vitro activity against malaria parasites, including parasites that are highly resistant to available antimalarial drugs.

Representative examples have also been shown to have potent in vivo activity against malaria parasites in animal models. Pharmaceutical compositions comprising these compounds, as well as methods of using the compounds to treat or prevent a malarial infection of a host, are claimed. The relative structural simplicity of this class of compounds, and the ready synthetic access thereto, provide unprecedented opportunities for structure-activity relationship (SAR), lead-optimization and antimalarial drug development. The technology is further described in the following publications: J. Nat Prod. 1997 Jul.;60(7):677–83 and Bioorg. Med. Chem. Lett. 1998 Jul.;8(13):1729–34.

Antimicrobial Magainin Peptides

Michael A. Zasloff, Hao-Chia Chen, Judith H. Brown, John L. Morell, Chang-Ming Huang (NICHHD). U.S. Patent 4,810,777 issued on 07 Mar 1989 (DHHS Reference No. E–145–1987/0–US–01); U.S. Patent 5,567,681 issued on 22 Oct 1996 (DHHS Reference No. E–145–1987/2–US–03);

U.S. Patent 5,643,876 issued on 01 Jul 1997 (DHHS Reference No. E–145–1987/1–US–03); U.S. Patent 5,221,732 issued on 22 Jun 1993 (DHHS Reference No. E–217–1988/0–US–01).

First isolated from the skin of the African clawed frog *Xenopus laevis*, magainin peptides have been shown by the inventors to have broad-spectrum antimicrobial properties. Both synthetic and natural magainin peptides are active against many species of bacteria and fungi and induce osmotic lysis of protozoa. Magainin peptides are water soluble, nonhemolytic at effective antimicrobial concentrations, have molecular weights of 2500 or less and are amphiphilic. Compositions and methods for their use are claimed in the patents. These inventions are available for nonexclusive or exclusive licensing. The inventions are further described in Zasloff *et al.*, P.N.A.S. USA 1987 Aug.; 84(15):5449–53; Marion *et al.*, FEBS Lett. 1988 Jan.18;227(1):21–6; Soravia *et al.*, FEBS Lett. 1988 Feb. 15;228(2):337–40; Westerhoff *et al.*, P.N.A.S. USA 1989 Sep.; 86(17):6597–601; and Gwadz *et al.*, Infect. Immun. 1989 Sep.; 57(9):2628–33.

Dated: October 24, 2003.

Steven M. Ferguson,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 03–28060 Filed 11–6–03; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Initial Review Group, Subcommittee C—Basic & Preclinical.

Date: December 9–10, 2003.

Time: 7 p.m. to 6 p.m.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn Select Bethesda, 8120 Wisconsin Ave, Bethesda, MD 20814.

Contact Person: Michael B. Small, PhD., Scientific Review Administrator, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, Room 8127, Bethesda, MD 20892, 301–402–0996, smallm@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: October 30, 2003.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 03–28033 Filed 11–6–03; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Center for Research Resources; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Center for Research Resources Special Emphasis Panel Clinical Research.

Date: November 12–13, 2003.

Time: November 12, 2003, 7:45 a.m. to Adjournment.

Agenda: To review and evaluate grant applications.

Place: University Place, 850 West Michigan Street, Indianapolis, IN 46202.

Contact Person: Marc Rigas, PhD., Scientific Review Administrator, National Center For Research Resources, or, National Institutes of Health, 6701 Democracy Blvd., 1 Democracy Plaza, rm 1080, MSC 4874,

Bethesda, MD 20817-4874, 301-435-0806, rigasm@mail.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: National Center for Research Resources Special Emphasis Panel Clinical Research.

Date: December 3-4, 2003.

Time: December 3, 2003, 7:45 a.m. to Adjournment.

Agenda: To review and evaluate grant applications.

Place: Radisson Plaza Lord, Baltimore 20 W. Baltimore Street, Baltimore, MD 02115.

Contact Person: Mohan Viswanathan, PhD., Scientific Review Administrator, Office of Review, National Institutes of Health, 6701 Democracy Boulevard, 1 Democracy Plaza room 1084, Bethesda, MD 20892-4874, 301-435-0829, viswanathanm@ncrr.nih.gov.

Name of Committee: National Center for Research Resources Special Emphasis Panel Comparative Medicine.

Date: January 27-29, 2004.

Time: January 27, 2004, 8 a.m. to Adjournment.

Agenda: To review and evaluate grant applications.

Place: Hyatt Regency, 123 Lesoya Street, San Antonio, TX 78205.

Contact Person: Carol Lambert, PhD., Scientific Review Administrator, Office of Review, National Center for Research Resources, National Institute of Health, 6701 Democracy Boulevard, 1 Democracy Plaza, room 1076, Bethesda, MD 20892-4874, (301) 435-0814, lambert@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research; 93.371, Biomedical Technology; 93.389, Research Infrastructure, 93.306, 93.333, National Institutes of Health, HHS)

Dated: October 31, 2003.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 03-28035 Filed 11-6-03; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Mental Health; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial

property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Mental Health Special Emphasis Panel NIMH COR Research Training and Education Grants.

Date: November 24, 2003.

Time: 9 a.m. to 1 p.m.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn Select Bethesda, 8120 Wisconsin Ave, Bethesda, MD 20814.

Contact Person: Richard E. Weise, PhD., Scientific Review Administrator, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Boulevard, room 6140, MS9606, Bethesda, MD 20892-9606, 301-443-1225, rweise@mail.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.242, Mental Health Research Grants; 93.281, Scientist Development Award, Scientist Development Award for Clinicians, and Research Scientist Award; 93.282, Mental Health National Research Service Awards for Research Training, National Institutes of Health, HHS)

Dated: October 30, 2003.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 03-28032 Filed 11-6-03; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Environmental Health Sciences; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Institute of Environmental Health Sciences Special Emphasis Panel, November 19, 2003, 1:30 p.m. to November 19, 2003, 2:30 p.m., NIEHS/National Institutes of Health, Building 4401, East Campus, 79 T.W. Alexander Drive, 122, Research Triangle Park, NC 27709 which was published in the **Federal Register** on October 22, 2003, 68 FR 60404.

The meeting will be held on November 24, 2003 at 2 p.m. The meeting is closed to the public.

Dated: October 31, 2003.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 03-28036 Filed 11-6-03; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institutes of Environmental Health Sciences; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Institute of Environmental Health Sciences Special Emphasis Panel, November 12, 2003, 3 p.m. to November 12, 2003, 4 p.m., NIEHS/National Institutes of Health, Building 4401, East Campus, 79 T.W. Alexander Drive, 122, Research Triangle Park, NC, 27709 which was published in the **Federal Register** on November 22, 2003, 68 FR 60404.

The telephone conference meeting will be held November 20, 2003 at 3 p.m. The meeting is closed to the public.

Dated: October 31, 2003.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 03-28037 Filed 11-6-03; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Environmental Health Sciences; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Institute of Environmental Health Sciences Special Emphasis Panel, October 28, 2003, 10 a.m. to October 28, 2003, 1 p.m., NIEHS/National Institutes of Health, Building 4401, East Campus, 79 T.W. Alexander Drive, 122, Research Triangle Park, NC 27709 which was published in the **Federal Register** on September 25, 2003, 69 FR 55401.

The meeting will be held November 17, 2003 at 11 a.m. The meeting is closed to the public.

Dated: October 31, 2003.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 03-28038 Filed 11-6-03; 8:45 am]

BILLING CODE 4140-01-M